Postmenopauzal'nyy osteoporoz kak mediko-sotsial'naya i ekonomicheskaya problema XXI v


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Postmenopausal osteoporosis (PMO) can be justly considered as significant medical and social problem, which is characterized by high prevalence in the population of women over age of 50 years and severity of complications. Bone fractures on the background of the PMO are associated with decreased quality of life, increased mortality, and economic losses of the healthcare system. Wide and timely appointment of effective pathogenetical therapy with a convenient dosage regimen provides high quality of treatment of the disease and allows to reduce the incidence of fractures associated with osteoporosis. Widespread use of bisphosphonates has played an invaluable role in addressing the problem of treatment of osteoporosis. Ibandronic acid is one of the most widely used bisphosphonate in the world.

Full Text

Restricted Access

About the authors

L. A Marchenkova

Email: MarchenkovaLA@rncmrik.com

References

  1. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24:23-57.
  2. Bleibler F., Konnopka A., Benzinger P., Rapp K., König H.H. The health burden and costs of incident fractures attributable to osteoporosis from 2010 to 2050 in Germany - a demographic simulation mode. Osteoporos Int. 2013;24:835-47.
  3. Stone K.L., Seeley D.G., Lui L.Y., Cauley J.A.,Ensrud K., Browner W.S., Nevitt M.C., Cummings S.R. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J. Bone Miner. Res. 2003; 18:1947-54.
  4. Melton L.J. 3rd, Thamer M., Ray N.F., Chan J.K., Chesnut C.H. 3rd, Einhorn T.A., Johnston C.C., Raisz L.G., Silverman S.L., Siris E. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 1997;12:16-23.
  5. Melton L.J. 3rd. Epidemiology of fractures. In: Riggs B.L., Melton L.J. eds. Osteoporosis: etiology, diagnosis, and management, 2nd ed. Philadelphia, Lippincott-Raven. 1995. P. 225-47.
  6. Kanis J.A., Bianchi G., Bilezikian J.P., Kaufman J.M., Khosla S., Orwoll E., Seeman E. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011; 22:2789-98.
  7. Mихайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. В кн.: «Руководство по остеопорозу» / Под ред. Л.И. Беневоленской. М., 2003.
  8. Михайлов Е.Е., Беневоленская Л.И., Баркова Т. В. Эпидемиологическаяхарактеристика переломов конечностей в популяционной выборке лиц 50 лет и старше. Остеопороз и остеопатии. 1998;2:2-6.
  9. Древаль, А.В., Марченкова Л.А., Мылов Н.М., Новосельцева И.А., Оноприенко Г.А., Шумский В.И. Сравнительная информативность денситометрии осевого и периферического скелета и рентгенографии в диагностике постменопаузального остеопороза. Остеопороз и остеопатии. 1999;1:25-8.
  10. Cheng S.Y., Levy A.R., Lefaivre K.A., Guy P., Kuramoto L., Sobolev B. Geographic trends in incidence of hip fractures: a compre- hensive literature review. Osteoporos Int. 2011; 22:2575-86.
  11. Kanis J.A., Odеn A., McCloskey E.V., Johansson H., Wahl D.A., Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239-56.
  12. Михайлов Е.Е., Беневоленская Л.И., Аникин С.Г. Частота переломов проксимального отдела бедренной кости и дистального отдела предплечья среди городского населения России. Остеопороз и остеопатии. 1999;3: 2-6.
  13. Древаль А.В., Марченкова Л.А., Крюкова И.В. Частота переломов бедра и предплечья и затраты на их лечение в Московской области. Остеопороз и остеопатии. 2005;2:8-13.
  14. O'Neill T.W., Felsenberg D., Varlow J., Cooper С, Kanis J.A., Silman A.J. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J. Bone Miner. Res. 1996;11: 1010-18.
  15. Евстигнеева Л. П., Лесняк О. М., Пивень А. И. Эпидемиология остеопоротических переломов позвоночника по данным рентгеноморфометрического анализа среди популяционной выборки жителей г. Екатеринбурга 50 лет и старше. Остеопороз и остеопатии. 2001;2:2-6.
  16. Михайлов Е.Е., Беневоленская Л.И., Мылов Н.М. Распространенность переломов позвоночника в популяционной выборке лиц 50 лет и старше. Вестник травматологии и ортопедии им. Н.Н. Приорова. 1997;3:20-7.
  17. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., Kanis J. Health-related quality of life (HRQOL) in postmenopausal women with low BMD with or without prevalent vertebral fracture. J. Bone Miner. Res. 2000;15:1384-92.
  18. Kanis J.A., Johnell O., Oden A., Borgstrom F., Zethraeus N., De Laet C., Jonsson B. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15:20-6.
  19. Kanis J.A., Johnell О. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229-38.
  20. Bessette L., Jean S., Lapointe-Garant M.P., Belzile E.L, Davison K.S., Ste-Marie L.G., Brown J.P. Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. Osteoporosis Int. 2012;23:1757-68.
  21. Kanis J.A., Compston J., Cooper C., et al. The burden of fractures in the European Union in 2010. Osteoporos Int. 2012; 23(Suppl. 2):57.
  22. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 2005;22:465-75.
  23. Piscitelli P., lolascon G., Gimigliano F., Muratore M., Camboa P., Borgia O., Forcina B., Fitto F., Robaud V., Termini G., Rini G.B., Gianicolo E., Faino A., Rossini M., Adami S., Angeli A., Distante A., Gatto S., Gimigliano R., Guida G. Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int. 2007;18:211-19.
  24. Pfeilschifter J., Cooper C., Watts N.B., Flahive J., Saag K.G., Adachi J.D., Boonen S., Chapurlat R., Compston J.E., Diez-Perez A., LaCroix A.Z., Netelenbos J.C., Rossini M., Roux C., Sambrook P.N., Silverman S., Siris E.S. Regional and age-related variations in the proportions of hip fractures and major fractuœs among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporos Int. 2012; 23:2179-88.
  25. Lippuner K., Grifone S., Schwenkglenks M., Schwab P., Popp A.W., Senn C., Perrelet R. Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. Osteoporos Int. 2012;23:829-39.
  26. McGowan B., Casey M. C., Silke C., Whelan B., Bennett K. Hospitalisations for fracture and associated costs between 2000 and 2009 in Ireland: a trend analysis. Osteoporos Int. 2013;24:849-57.
  27. Roux C., Wyman A., Hooven F. H., Gehlbach S.H., Adachi J.D., Chapurlat R.D., Compston J.E., Cooper C., Diez-Perez A., Greenspan S.L., Lacroix A.Z., Netelenbos J.C., Pfeilschifter J.,Rossini M., Saag K.G., Sambrook P.N., Silverman S., Siris E.S., Watts N.B., Boonen S. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women. Osteoporos Int. 2012;23:2863-71.
  28. Bianchi M.L., Orsini M.R., Saraifoger S., Ortolani S., Radaelli G., Betti S. Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes. 2005;3:78.
  29. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am. J. Med. 1997;103(Suppl. 2A):12-9.
  30. Norton R., Butler M., Robinson E., Lee-Joe T., Campbell A.J. Declines in physical functioning attributable to hip fracture among older people: a follow-up study of case-control participant. Disability Rehabilitation. 2000;22: 345-51.
  31. Меньшикова Л.В., Храмцова Н.А. Ретроспективное изучение частоты переломов проксимального отдела бедра и дистального отдела предплечья среди жителей Иркутской области. Остеопороз и остеопатии. 2000;4:5-8.
  32. Кузьмина Л.И., Лесняк О.М., Кузнецова И.Л. Медико-социальные последствия перелома шейки бедра у пожилых. Клиническая геронтология. 2001; 7(9):22-7.
  33. Гладкова Е.Н., Ходырев В.Н., Лесняк О.М. Анализ двигательной активности после перелома проксимального отдела бедра в популяции городских жителей Свердловской области. Материалы научно -практической конференции «Остеопороз важнейшая мультидисциплинарная проблема XXI века». СПб., 23-25 сентября 2012. C. 15-9.
  34. Лесняк О.М., Бахтиярова С.А., Голобородько К.Н., Кузнецова Н.Л. Качество жизни при остеопорозе. Проспективное наблюдение пациентов, перенесших перелом проксимального отдела бедра. Остеопороз и остеопатии. 2007;3:4-8.
  35. Lips P., van Schoor N.M. Quality of life in patients with osteoporosis. Osteoporos Int. 2005;16:447-55.
  36. Меньшикова Л.В. Исходы переломов бедренной кости и их медико-социальные последствия. Клинич. медицина. 2002; 6:39-41.
  37. Марченкова Л.А., Прохорова Е.А., Древаль А.В., Полякова Е.Ю., Петухова Н.Ю., Вишнякова М.В. Влияние постменопаузального остеопороза и субклинических компрессионных переломов позвонков на качество жизни женщин в постменопауз. Альманах клин. медицины. 2014;32:43-9.
  38. Kanis J.A, Compston J., Cooper C., et al. The burden of fractures in the European Union in 2010. Osteoporos int. 2012; 23(Suppl. 2):S57.
  39. ioannidis G., Papaioannou A., Hopman W.M., Akhtar-Danesh N.,Anastassiades T., Pickard L., Kennedy C.C., Prior J.C., Olszynski W.P., Davison K.S., Goltzman D., Thabane L., Gafni A., Papadimitropoulos E.A., Brown J.P., Josse R.G., Hanley D.A., Adachi J.D. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Can Med. Assoc. J. 2009;181:265-71.
  40. LeBlanc E.S., Hillier T.A., Pedula K.L., Rizzo J.H., Cawthon P.M., Fink H.A., Cauley J.A., Bauer D.C., Black D.M., Cummings S.R., Browner W.S. Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch. intern. Med. 2011;171:1831-37.
  41. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513-21.
  42. Koh G. C.-H., Tai B.C., Ang L.-W., Heng D., Yuan J.M., Koh W.P. All-cause and cause-specific mortality after hip fracture among Chinese women and men. Osteoporos int. 2013;24:1981-89.
  43. Melton L.J. 3rd, Achenbach S.J., Atkinson E.J., Therneau T.M., Amin S. Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos int. 2013;24:1689-96.
  44. Ziade N., Jougla E., Coste J. Population-level impact of osteoporotic fractures on mortality and trends over time: a nationwide analysis of vital statistics for France, 1968-2004. Am. J. Epidemiol. 2010;172:942-51.
  45. Nikitovic M., Wodchis W.P., Krahn M.D., Cadarette S.M. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos int. 2013; 24:659-69.
  46. Abrahamsen B., van Staa T., Ariely R., Olson M., Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos int. 2009;20:1633-50.
  47. Gronskag А.B., Romundstad P., Forsmo S., Langhammer A., Schei B. Excess mortality after hip fracture among elderly women in Norway. Osteoporos int. 2012;23:1807-11.
  48. Morin S., Lix L.M., Azimaee M., Metge C., Caetano P., Leslie W.D. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos int. 2011; 22:2439-48.
  49. Van der Jagt-Willems H.C., Vis M., Tulner C.R., van Campen J.P., Woolf A.D., van Munster B.C., Lems W.F. Mortality and incident vertebral fractures after 3 years of follow-up among geriatric patients. Osteoporos int. 2013;24:1713-19.
  50. Prieto-Alhambra D., Aviles F. F., Judge A. Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality. Osteoporos int. 2012;23:2797-803.
  51. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82.
  52. Lee Y.-K., Jang S., Jang S., Lee H.J., Park C., Ha Y.C., Kim D.Y. Mortality after vertebral fracture in Korea. Osteoporos int. 2012;23:1859-65.
  53. Grey A., Bolland M.J. The effect of treatments for osteoporosis on mortality. Osteoporos int. 2013;24:1-6.
  54. Chesnut C.H. 3rd, Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.C., Delmas P.D. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 2004;19:1241-49.
  55. Felsenberg D., Miller P., Armbrecht G., Wilson K., Schimmer R.C., Papapoulos S.E. Oral ibandronate significantly reduces the risof vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone. 2005;37:651-54.
  56. Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr. Med. Res. Opin. 2009;25:2951-60.
  57. Cranney A., Wells G.A., Yetisir E., Adami S., Cooper C., Delmas P.D., Miller P.D., Papapoulos S., Reginster J.Y., Sambrook P.N., Silverman S., Siris E., Adachi J.D. ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos. int. 2009;20:291-97.
  58. Harris S.T., Blumentals W.A., Miller P.D. ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase 3 studies. Curr. Ned. Res. Opin. 2005; 24:237-45.
  59. Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid i.R., Delmas P., Zoog H.B., Austin M., Wang A., Kutilek S., Adami S., ZanchettaJ., Libanati C.,Siddhanti S., Christiansen C. FREEDOM Trial: Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2009;361:756-65.
  60. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsen-berg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBiLE study. J. Bone and Miner. Res. 2005;20:1315-22.
  61. Reginster J.-Y., Adami S., Lakatos S., Greenwald M., Stepan J.J., Silverman S.L., Christiansen C., Rowell L., Mairon N., Bonvoisin B., Drezner M.K., Emkey R., Felsenberg D., Cooper C., Delmas P.D., Miller P.D. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBiLE study. Ann. Rheum. Dis. 2006;65:654-61.
  62. Delmas P.D., Adami S., Strugala C., Stakkestad J.A., Reginster J.Y., Felsenberg D., Christiansen C., Civitelli R., Drezner M.K., Recker R.R., Bolognese M., Hughes C., Masanauskaite D., Ward P., Sambrook P., Reid D.M. intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthrit. Rheumat. 2006;54:1838-46.
  63. Eisman J.A., Civitelli R., Adami S., Czerwinski E., Recknor C., Prince R., Reginster J.Y., Zaidi M., Felsenberg D., Hughes C., Mairon N., Masanauskaite D., Reid D.M., Delmas P.D., Recker R.R. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: a 2-year results from the DiVA study. J. Rheumatol. 2008;35:488-97.
  64. Campbel M.J., Machin D. Medical Statistis a commonsense approach. 2003. P. 62-3.
  65. Lewiecki E.M., Keaveny T.M., Kopperdahl D.L., Genant H.K., Engelke K., Fuerst T., Kivitz A., Davies R.Y., Fitzpatrick L.A. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2009;94:171-80.
  66. Genant H.K., Lewiecki E.M., Fuerst T., Fries M. Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporosis Int. 2012; 23:257-65.
  67. Chapurlat R.D., Laroche M., Thomas T., Rouanet S., Delmas P.D., de Vernejoul M.C. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia - a randomized placebo-controlled trial. Osteoporosis Int. 2013;24:311-20.
  68. Recker R.R., Ste-Marie L.G., Langdahl B., Masanauskaite D., Ethgen D., Delmas P.D. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe stud. J. Clin. Densitom. 2009;12:71-6.
  69. Bock O., Borst H., Beller G., Armbrecht G., Degner C., Martus P., Roth H.J., Felsenberg D. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo muCT. Bone. 2012; 50:317-24.
  70. Recker R.R., Ste-Marie L.G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D., Rowell L., Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010; 46:660-65.
  71. Bala Y., Kohles J., Recker R.R., Boivin G. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Calcified. Tissue Int. 2013;92:6-14.
  72. Kanis J.A., Cooper C., Hiligsmann M., Rabenda V., Reginster J.Y., Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011; 22:2565-73.
  73. Siris E., Rosen C.J., Harris S.T., Barr C.E., Arvesen J.N., Abbott T.A., Silverman S. Adherence to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Mayo Clin. Proc. 2006;81:1013-22.
  74. Soong Y.-K., Tsai K.-S., Huang H.-Y., Yang R.S., Chen J.F., Wu P.C., Huang K.E. Risk of refracture associated with compliance and persistence with bisphosphonate ther apy in Taiwan. Osteoporos Int. 2013;24: 511-21.
  75. Hansen C., Pedersen B.D., Konradsen B.H. Anti-osteoporotic therapy in Denmark predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int. 2013; 2:2079-97.
  76. Landfeldt E., Ström O., Robbins S., Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012;23:433-43.
  77. Cotte F.E., Fardellone P., Mercier F., Gaudin A.F., Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis Int. 2010;21:145-55.
  78. Gatti D., Rossini M., Viapiana O., et.al. Adherence to oral osteoporosis treatment in the Italian clinical practice. Reumatismo. 2010;62(Suppl.):1-8.
  79. Rossini M., Di Munno O., Gatti D., Giannini S., Minisola S., Varenna M., Adami S. Optimizing bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. Clin. Exp. Rheumatol. 2011;29:728-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies